Stay updated on Psilocybin-Induced Neuroplasticity in MDD Clinical Trial
Sign up to get notified when there's something new on the Psilocybin-Induced Neuroplasticity in MDD Clinical Trial page.

Latest updates to the Psilocybin-Induced Neuroplasticity in MDD Clinical Trial page
- Check3 days agoChange DetectedMinor update: version bumped from v3.0.1 to v3.0.2, with the 'Back to Top' element removed.SummaryDifference0.3%
- Check10 days agoChange DetectedThe web page has been updated from version 3.0.0 to version 3.0.1, indicating a revision in the content.SummaryDifference0.3%
- Check17 days agoChange DetectedThe web page has undergone significant updates, including the addition of a facility name and location, as well as new content related to drug safety and various pharmaceutical classifications. Notably, previous content regarding genetics and specific drug effects has been removed.SummaryDifference4%
- Check24 days agoNo Change Detected
- Check32 days agoChange DetectedThe web page has been updated from version 2.16.11 to version 2.16.12.SummaryDifference0.1%
- Check39 days agoChange DetectedThe webpage has updated its version from v2.16.10 to v2.16.11 and has added new dates for August and September 2025 while removing previous dates from May and June 2025.SummaryDifference1%
- Check46 days agoChange DetectedThe web page has added a new clinical study on psilocybin's effects on major depressive disorder, sponsored by Yale University, which includes detailed information about the study's design, eligibility criteria, and outcome measures. Additionally, the page now includes a disclaimer about the U.S. government's non-review of all studies listed.SummaryDifference100%
Stay in the know with updates to Psilocybin-Induced Neuroplasticity in MDD Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Psilocybin-Induced Neuroplasticity in MDD Clinical Trial page.